Eric Baudin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oral Presentation at ESMO will feature updated results from Phase 1/2 SPENCER studyPARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that updated data from its Phase 1/2 SPENCER study on EO2401, in combination with nivolumab in patients with adrenal tumors, will be presented in an oral session at the European

First presentation of results from CheckMate -901 show survival benefit with Opdivo + chemotherapy in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma who...

177Lutetium-octreotate can improve progression-free survival vs sunitinib in patients with progressive pancreatic neuroendocrine tumors.

177Lutetium-octreotate can improve progression-free survival vs sunitinib in patients with progressive pancreatic neuroendocrine tumors.

Enterome is evaluating EO2401 in Phase 1/2 clinical trials in recurrent glioblastoma (ROSALIE) and adrenocortical malignancies (SPENCER) Proof-of-concept data...